Month: November 2022

On July 21, 2017, Zhang, Zhaochao; Li, Chong; Tang, Dandan; Jin, Weixin; Wang, Miao published a patent.Electric Literature of 63931-21-5 The title of the patent was Organic compounds based on pyridine and benzimidazole use as OLED device. And the patent contained the following:

The present invention provides chem. structural formula I of the organic compound, in which X1-X6 independently represents N or C atom, the number of N atoms is 2; p is 0, 1, 2, 3 or 4; m or n independently represents 0, 1, 2 or 3, m+n+z=4, Ar1-3 independently represents C1-10 linear chain or branched chain alkyl, halogen atom, protinium, deuterium, triterium atom substituted or unsubstituted Ph, naphthyl, anthracyl or pyridyl; pyrimidyl, pyrazinyl, pyridazinyl, dibenzopyrane, 9,9-di-Me fluorene, N-Ph carbazole, quinolyl, isoquinolyl or naphthyridinyl, Ar1 also represents single bond etc. The compound of this invention has higher glass transition temperature and mol. heat endurance; and it has low absorptivity and high refractive index in visible light domain. After applied to the CPL layer of OLED device, title compound can effectively enhance the light extraction efficiency of OLED device. The compound of this invention also has deep HOMO energy level and high electron mobility, so it can be used as material of hole barrier/electron transport layer of OLED device, and can effectively stop the conveyance of hole or energy from luminescent layer to electronic shell side, so as to enhance the compounding efficiency of hole and electron in luminescent layer, and enhance the luminous efficiency and service life of OLED device. The experimental process involved the reaction of 5-Bromo-2,4,6-trichloropyrimidine(cas: 63931-21-5).Electric Literature of 63931-21-5

The Article related to pyridine benzimidazole oled, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Electric Literature of 63931-21-5

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Wang, Han; Wen, Kun; Wang, Le; Xiang, Ye; Xu, Xiaocheng; Shen, Yongjia; Sun, Zhihua published an article in 2012, the title of the article was Large-scale solvent-free chlorination of hydroxy-pyrimidines, -pyridines, -pyrazines and -amides using equimolar POCl3.Safety of 6-Methylpyrimidine-2,4(1H,3H)-dione And the article contains the following content:

Chlorination with equimolar POCl3 can be efficiently achieved not only for hydroxypyrimidines, but also for many other substrates such as 2-hydroxypyridines, -quinoxalines, or even -amides. The procedure is solvent-free and involves heating in a sealed reactor at high temperatures using one equivalent of pyridine as base. It is suitable for large scale (multigram) batch preparations The experimental process involved the reaction of 6-Methylpyrimidine-2,4(1H,3H)-dione(cas: 626-48-2).Safety of 6-Methylpyrimidine-2,4(1H,3H)-dione

The Article related to chlorination hydroxy pyrimidine pyridine quinoxaline, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Safety of 6-Methylpyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On April 16, 2020, Liu, Shiqiang; Yuan, Yida; Bao, Meng; Huang, Shengai; Bao, Rudi published a patent.COA of Formula: C6H6ClN3O2 The title of the patent was Regulator of nitrogen-containing heteroaromatic derivatives, preparation method and application.. And the patent contained the following:

The invention disclosed a kind of regulator of nitrogen-containing heteroaromatic derivatives, their preparation method and application. The claimed compound is shown in structure I (W = CR4 or N; Q = CR5 or N; R4,R5 = H, D, alkyl, haloalkyl, etc.; L1 = bond, O, S, alkylene, alkenyl, etc.; L2 == bond , O or S; ring A = cycloalkyl, heterocyclo, aryl, heteroaryl, etc.; ring B = cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R1 = H, D, alkyl, halo, etc.; R2 = H, D, halolakyl, amino, nitro, etc.; R3 = alkyl, alkenyl, alkynyl, etc.; x,y = 0, 1-5 integers). The claimed compound is prepared via multiple steps (procedure given). The prepared compound can be used as protein tyrosine phosphatase-2C (SHP2) inhibitor, can be used for treating diseases or conditions such as Noonan syndrome, leopard skin syndrome, leukemia, neuroblastoma, melanoma, esophageal cancer, head and neck tumors, breast cancer, lung cancer and colon cancer, etc. , preferably non-small cell lung cancer, esophagus cancer and head and neck tumors. The experimental process involved the reaction of Methyl 6-amino-2-chloropyrimidine-4-carboxylate(cas: 944129-00-4).COA of Formula: C6H6ClN3O2

The Article related to heteroaromatic derivative preparation shp2 inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.COA of Formula: C6H6ClN3O2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On February 11, 2020, Xing, Qifeng; Feng, Peichuan; Chen, Yue; Hu, Lingfeng; Chen, Yili published a patent.HPLC of Formula: 160377-42-4 The title of the patent was Organic compounds and its applications. And the patent contained the following:

An organic compound having simple and easy implementation, readily available raw materials, suitable for mass production scale-up and used as light emitting layer in an OLED device is provided. The class of organic compounds is represented by the following structural formula I as an example. The application of organic compound used in organic electroluminescent device. The experimental process involved the reaction of 5-(4-Bromophenyl)pyrimidine(cas: 160377-42-4).HPLC of Formula: 160377-42-4

The Article related to organic compound application electroluminescent device, Heterocyclic Compounds (More Than One Hetero Atom): Other 6-Membered Rings, Three Or More Hetero Atoms and other aspects.HPLC of Formula: 160377-42-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On January 26, 2018, Wang, Fang; Zhang, Zhaochao; Li, Chong; Zhang, Xiaoqing published a patent.Category: pyrimidines The title of the patent was Process for preparation of organic compound based on pyridine and quinoxaline. And the patent contained the following:

The invention relates to preparation of organic compound based on pyridine and quinoxaline and application to OLED device. Compound I was prepared via multi step synthesis with coupling reactions as key steps. The compound has low absorption and high refractive index in visible light field, and can effectively improve light extraction efficiency of the OLED device when applied to CPL layer of the OLED device. The compound has deep HOMO energy level and high electronic mobility, can be used as a hole blocking/electron transport layer material of the OLED device, and can effectively block the hole or energy from being transferred from a light-emitting layer to one side of an electronic layer, so as to improve compounding efficiency of the hole and electron in the light-emitting layer, and further improve light emission efficiency and prolong service life of the OLED device. The experimental process involved the reaction of 5-Bromo-2,4,6-trichloropyrimidine(cas: 63931-21-5).Category: pyrimidines

The Article related to quinoxaline pyridine based organ compound preparation oled, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Category: pyrimidines

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On November 23, 2017, Fischer, John P.; Fell, Jay Bradford; Blake, James F.; Hinklin, Ronald Jay; Mejia, Macedonio J.; Hicken, Erik James; Chicarelli, Mark Joseph; Gaudino, John J.; Vigers, Guy P.A.; Burgess, Laurence E.; Marx, Matthew Arnold; Christensen, James Gail; Lee, Matthew Randolf; Savechenkov, Pavel; Zecca, Henry J. published a patent.Related Products of 175357-98-9 The title of the patent was Preparation of substituted pyridopyrimidines as KRas G12C inhibitors for treating cancer. And the patent contained the following:

The title compounds I [X = (un)substituted 4-12 membered saturated or partially saturated monocyclic, bridged or spirocyclic ring; Y = a bond, O, S or NR5; R1 = C(O)C(Ra)( or =)C(Rb)p or SO2C(Ra)( or =)C(Rb)p; R2 = H, alkyl, hydroxyalkyl, etc.; R3 = (independently) alkyl, oxo, haloalkyl; L = a bond, C(O), alkylene; R4 = H, cycloalkyl, heterocyclyl, etc.; R5 = (independently) H, alkyl; m = 0-2; Ra = absent, H, alkyl; each Rb = (independently) H, alkyl, alkylaminylalkyl, dialkylaminylalkyl or heterocyclylalkyl; p = 0 or 2] or a pharmaceutically acceptable salts thereof that inhibit KRas G12C, were prepared E.g., a multi-step synthesis of II, starting from tert-Bu 4-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate and benzyl 1-piperazinecarboxylate, was described. Exemplified compounds I were tested for inhibition of KRas G12C activity (data given). In particular, the present invention relates to compounds I that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds I and methods of use therefor. The experimental process involved the reaction of 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine(cas: 175357-98-9).Related Products of 175357-98-9

The Article related to pyridopyrimidine preparation kras g12c inhibitor antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Related Products of 175357-98-9

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On February 11, 2016, Claremon, David A.; Dong, Chengguo; Fan, Yi; Leftheris, Katerina; Lotesta, Stephen D.; Singh, Suresh B.; Tice, Colin M.; Zhao, Wei; Zheng, Yajun; Zhuang, Linghang published a patent.Electric Literature of 596114-50-0 The title of the patent was Preparation of piperazine derivatives as liver X receptor modulators. And the patent contained the following:

Provided are novel compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are liver X receptor modulators, and which are useful in the treatment of diseases and disorders associated with the liver X receptor. Also provided are the compounds of formula I and pharmaceutical compositions thereof for treating atherosclerosis, cardiovascular disease, Alzheimer’s disease, dermatitis, dyslipidemia, cancer and other diseases or disorders. Title compounds I [Q = alkyl-OC(O), heteroaryl, aryl-alkyl-OC(O), etc.; R1 = alkyl, cycloalkyl, aryl-alkyl, etc.; R2 = H, halo, cyano, etc.; R3 = alkyl, halo-alkyl, cycloalkyl, etc.; R4 = H or alkyl], and their pharmaceutically acceptable salts, are prepared Thus, e.g., II was prepared by reaction of (R)-tert-Bu 2-isopropylpiperazine-1-carboxylate with [3-(methylsulfonyl)phenyl]boronic acid. Compounds of the invention were evaluated for their LXr α/β binding ad agonist activity, e.g., II showed Ki value of 1690 nM and 157 nM on LXRα and LXRβ, resp. The experimental process involved the reaction of 2-Chloro-5-isopropylpyrimidine(cas: 596114-50-0).Electric Literature of 596114-50-0

The Article related to piperazine derivative preparation liver receptor lxr modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Electric Literature of 596114-50-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On February 11, 2016, Claremon, David A.; Dong, Chengguo; Fan, Yi; Leftheris, Katerina; Lotesta, Stephen D.; Singh, Suresh B.; Tice, Colin M.; Zhao, Wei; Zheng, Yajun; Zhuang, Linghang published a patent.Quality Control of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine The title of the patent was Preparation of piperazine derivatives as liver X receptor modulators. And the patent contained the following:

Provided are novel compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are liver X receptor modulators, and which are useful in the treatment of diseases and disorders associated with the liver X receptor. Also provided are the compounds of formula I and pharmaceutical compositions thereof for treating atherosclerosis, cardiovascular disease, Alzheimer’s disease, dermatitis, dyslipidemia, cancer and other diseases or disorders. Title compounds I [Q = alkyl-OC(O), heteroaryl, aryl-alkyl-OC(O), etc.; R1 = alkyl, cycloalkyl, aryl-alkyl, etc.; R2 = H, halo, cyano, etc.; R3 = alkyl, halo-alkyl, cycloalkyl, etc.; R4 = H or alkyl], and their pharmaceutically acceptable salts, are prepared Thus, e.g., II was prepared by reaction of (R)-tert-Bu 2-isopropylpiperazine-1-carboxylate with [3-(methylsulfonyl)phenyl]boronic acid. Compounds of the invention were evaluated for their LXr α/β binding ad agonist activity, e.g., II showed Ki value of 1690 nM and 157 nM on LXRα and LXRβ, resp. The experimental process involved the reaction of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine(cas: 785777-98-2).Quality Control of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine

The Article related to piperazine derivative preparation liver receptor lxr modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Quality Control of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On October 14, 1999, Matsuno, Kenji; Nomoto, Yuji; Ichimura, Michio; Ide, Shin-ichi; Oda, Shoji published a patent.COA of Formula: C7H3ClFN3 The title of the patent was Preparation of nitrogenous heterocyclic compounds for inhibiting phosphorylation of PDGF receptors. And the patent contained the following:

Nitrogenous heterocyclic compounds [I; W = 1,4-piperazinediyl, etc.; U = NR1R2 (wherein R1 = H, (un)substituted alkyl, etc.; R2 = H, etc.), OR4 or SR5 (wherein R4, R5 = (un)substituted alkyl, alicyclic alkyl, heterocyclic, etc.); V = O, S, NR6, or CR7R8 (wherein R6 = R1, cyano, OH, NO2, etc.; R7, R8 = H, cyano, NO2, etc.); at least one of X, Y, and Z = N and the remainder are the same or different and each represents N or CRA (wherein RA = R1, halo, cyano, NO2, etc.); and D1, D2, D3, and D4 each independently = N, O, S, CRB (wherein RB = RA), etc. or any adjacent two of D1-D4 in combination = N, O, S, etc.] or pharmacol. acceptable salts thereof, effective in inhibiting phosphorylation of PDGF receptors and in treating cell proliferation diseases such as arteriosclerosis, vascular reocclusion, cancers, glomerulosclerosis, etc., are prepared CF3CO2H was added to a solution of tert-Bu 4-[(4-phenoxyphenyl)carbamoyl]-1-piperazinecarboxylate in CH2Cl2 with stirring under cooling, the concentrate was dissolved in DMF containing Et3N and the solution was treated with 6-chloropurine under Ar at room temperature to give 71% N-(4-phenoxyphenyl)-4-(6-purinyl)-1-piperazinecarboxamide, which showed IC50 of 0.29 μM against phosphorylation of PDGF receptor. Four addnl. I showed 66-95% inhibition. Tablet, powder and syrup formulations were given. The experimental process involved the reaction of 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine(cas: 175357-98-9).COA of Formula: C7H3ClFN3

The Article related to phosphorylation inhibitor pdgf piperazinylquinazoline piperazinylpurine heterocyclylpiperazine preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.COA of Formula: C7H3ClFN3

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On August 4, 2010, Marhold, Albrecht; Ebenbeck, Wolfgang; Knauer, Stephan published a patent.Computed Properties of 785777-98-2 The title of the patent was Preparation of polyfluoro-N-heteroaromatics. And the patent contained the following:

A process for the preparation of title compounds I [X = N-heteroaromatic with provisos; A = fluoroalkyl, fluoroalkoxy, fluoroalkylthio; R1 = (R1′)n; R1′ = alkyl, aryl, arylalkyl; n = 0-1; Y = (Y’)m; Y’ = Cl, Br, F; m = 1-3] was disclosed. For example, HF/Autoclave(150°C) mediated fluorination of 2,4-dichloro-5-trichloropyrimidine afforded claimed polyfluoro-N-heteroaromatic II in 68% yield. The experimental process involved the reaction of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine(cas: 785777-98-2).Computed Properties of 785777-98-2

The Article related to polyfluoropyrazine preparation fluorination, polyfluoropyrimidine preparation fluorination, polyfluoropyridazine preparation fluorination, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Computed Properties of 785777-98-2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia